Peptomyc key facts
as of Oct 2026- Developer of cell-penetrating mini-protein therapeutics designed to treat cancer.
- Peptomyc is valued at approximately $40.5M as of Oct 2026 (last reported valuation).
- It has raised $25.0M; the latest was Later Stage VC ($5.8M) in Mar 2026.
- Notable investors include European Innovation Council, INNVIERTE SICC, Asabys Partners, Caixa Emprendedor XXI, ACCIÓ — 20 tracked in total.
- Status: Privately Held (backing).
Peptomyc's last reported valuation, Dec 2020. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Peptomyc: the Monday email on marks, rounds and moves
Peptomyc funding rounds
No funding rounds for Peptomyc are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Peptomyc
20+Peptomyc valuation
Peptomyc's last reported valuation was $40.5 million in Dec 2020. No priced round, secondary trade or fund mark has surfaced since.
Peptomyc investors
20 investors are on record for Peptomyc, including European Innovation Council, INNVIERTE SICC, Asabys Partners and Caixa Emprendedor XXI.
About Peptomyc
Developer of cell-penetrating mini-protein therapeutics designed to treat cancer. The company's therapeutics target the Myc oncogene, a central function in cancer cell survival, that lets cancer cells divide and survive treatment for the treatment of certain cancers of the lung and breast, as well as against brain tumors, enabling physicians and doctors to improve their chances of their patient's survival.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2014
- Employees
- 22
- Website
- peptomyc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.